MediciNova Announces MN-001 (tipelukast) Abstract regarding Lipid Metabolism in NASH/NAFLD Accepted for Presentation at The Liver Meeting® 2021, the Annual Meeting of the American Association for the Study of Liver Diseases
September 01 2021 - 6:30AM
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ
Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo
Stock Exchange (Code Number: 4875), today announced an abstract
entitled “Improvement of Intracellular Lipid Metabolism by
Tipelukast in the Pathogenesis of NASH/NAFLD" has
been selected for poster presentation at The Liver
Meeting® 2021, the annual meeting of the American Association for
the Study of Liver Diseases (AASLD) to be held November 12 - 15,
2021. MediciNova’s research collaborator, Dr. Masatsune Ogura,
Associate Professor at the Department of General Medical
Science, Chiba University Graduate School of Medicine, will present
the results of the study. Presentation details will be disseminated
as they become available.
“We are very pleased to present new findings
from our collaboration with Dr. Ogura which elucidate MN-001’s
ability to improve lipid metabolism. In particular, a new finding
is its ability to suppress intracellular triglyceride synthesis
which may account for the intracellular effect of MN-001 in
NASH/NAFLD patients in addition to significantly lowering serum
triglyceride levels,” commented Kazuko Matsuda, M.D. Ph.D, MPH.,
Chief Medical Officer, MediciNova, Inc.
About MN-001MN-001 (tipelukast)
is a novel, orally bioavailable, small molecule compound thought to
exert its effects through several mechanisms to produce its
anti-inflammatory and anti-fibrotic activity in preclinical models,
including leukotriene (LT) receptor antagonism, inhibition of
phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of
5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a
pathogenic factor in fibrosis development, and MN-001's inhibitory
effect on 5-LO and the 5-LO/LT pathway is considered to be a novel
approach to treat fibrosis. MN-001 has been shown to down-regulate
expression of genes that promote fibrosis including LOXL2, Collagen
Type 1 and TIMP-1. MN-001 has also been shown to down-regulate
expression of genes that promote inflammation including CCR2 and
MCP-1. In addition, histopathological data shows that MN-001
reduces fibrosis in multiple animal models.
About MediciNovaMediciNova,
Inc. is a clinical-stage biopharmaceutical company developing a
broad late-stage pipeline of novel small molecule therapies for
inflammatory, fibrotic, and neurodegenerative diseases. Based on
two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with
multiple mechanisms of action and strong safety profiles,
MediciNova has 11 programs in clinical development. MediciNova’s
lead asset, MN-166 (ibudilast), is currently in Phase 3 for
amyotrophic lateral sclerosis (ALS) and degenerative cervical
myelopathy (DCM) and is Phase 3-ready for progressive multiple
sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase
2 trials in glioblastoma, patients at risk of developing acute
respiratory distress syndrome (ARDS), and substance dependence.
MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic
pulmonary fibrosis (IPF) and is in preparation for a second Phase 2
trial in nonalcoholic steatohepatitis (NASH). MediciNova has a
strong track record of securing investigator-sponsored clinical
trials funded through government grants.
Statements in this press release that are not
historical in nature constitute forward-looking statements within
the meaning of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements
include, without limitation, statements regarding the future
development and efficacy of MN-166, MN-001, MN-221, and MN-029.
These forward-looking statements may be preceded by, followed by or
otherwise include the words "believes," "expects," "anticipates,"
"intends," "estimates," "projects," "can," "could," "may," "will,"
"would," “considering,” “planning” or similar expressions. These
forward-looking statements involve a number of risks and
uncertainties that may cause actual results or events to differ
materially from those expressed or implied by such forward-looking
statements. Factors that may cause actual results or events to
differ materially from those expressed or implied by these
forward-looking statements include, but are not limited to, risks
of obtaining future partner or grant funding for development of
MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient
capital when needed to fund MediciNova's operations and
contribution to clinical development, risks and uncertainties
inherent in clinical trials, including the potential cost, expected
timing and risks associated with clinical trials designed to meet
FDA guidance and the viability of further development considering
these factors, product development and commercialization risks, the
uncertainty of whether the results of clinical trials will be
predictive of results in later stages of product development, the
risk of delays or failure to obtain or maintain regulatory
approval, risks associated with the reliance on third parties to
sponsor and fund clinical trials, risks regarding intellectual
property rights in product candidates and the ability to defend and
enforce such intellectual property rights, the risk of failure of
the third parties upon whom MediciNova relies to conduct its
clinical trials and manufacture its product candidates to perform
as expected, the risk of increased cost and delays due to delays in
the commencement, enrollment, completion or analysis of clinical
trials or significant issues regarding the adequacy of clinical
trial designs or the execution of clinical trials, and the timing
of expected filings with the regulatory authorities, MediciNova's
collaborations with third parties, the availability of funds to
complete product development plans and MediciNova's ability to
obtain third party funding for programs and raise sufficient
capital when needed, and the other risks and uncertainties
described in MediciNova's filings with the Securities and Exchange
Commission, including its annual report on Form 10-K for the year
ended December 31, 2020 and its subsequent periodic reports on Form
10-Q and current reports on Form 8-K. Undue reliance should not be
placed on these forward-looking statements, which speak only as of
the date hereof. MediciNova disclaims any intent or obligation to
revise or update these forward-looking statements.
INVESTOR CONTACT:Geoff O'BrienVice
PresidentMediciNova, Inc.info@medicinova.com
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Medicinova (NASDAQ:MNOV)
Historical Stock Chart
From Apr 2023 to Apr 2024